K. Aben

Increasing and more consistent use of pre-biopsy MRI in prostate cancer diagnosis: insights from a population-based study in the Netherlands

C. C. Loeff, I. G. Schoots, P.J. van Leeuwen, D.E. Oprea-Lager et autres

nl (code pays fourni par la source)

Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer

J. Bosveld, B.B.M. Suelmann, MJ Bijlsma, M.D. Franken et autres

nl (code pays fourni par la source)

Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer

J. Bosveld, B.B.M. Suelmann, Maarten J. Bijlsma, Mira D. Franken et autres

2513P Treatment patterns and survival outcomes for metastatic castration sensitive prostate cancer: real-world evidence from four European countries

Chiara Barigazzi, M. Kuppen, Paul Gougis, Luigi Cerbone et autres

it, nl, fr, es, gb (code pays fourni par la source)

2500P Treatment intensification in the metastatic castration-sensitive prostate cancer landscape: real-world evidence from 4,559 patients in the CAPRI-3 registry

D. Andries Bosch, K.J.M. van der Velden, K. Aben, Florian Then Bergh et autres

nl (code pays fourni par la source)

P069 Risk-based Prostate Specific Antigen (PSA) monitoring reduces follow-up burden after radical prostatectomy

L.J. Paulino Pereira, Lambertus A. Kiemeney, I. Van Oort, K. Aben et autres

POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone

MS Holleman, Ivan Santi, Sammy Huygens, K. Aben et autres

nl (code pays fourni par la source)

Post-docetaxel survival in metastatic castration-resistant prostate cancer (mCRPC) is improving in the Netherlands

Hans M. Westgeest, M. Kuppen, F. Van Den Eertwegh, Jeroen van Moorselaar et autres

Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: An observational study in the Netherlands

Hans M. Westgeest, M. Kuppen, A.J.M. van den Eertwegh, Jeroen van Moorselaar et autres

nl (code pays fourni par la source)

PCN388 - PATIENT REPORTED OUTCOMES IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (PRO-CAPRI) IN THE NETHERLANDS

M. Kuppen, Hans M. Westgeest, A van den Eertwegh, R. Jeroen A. van Moorselaar et autres

nl (code pays fourni par la source)

Elderly prostate cancer patients in the Netherlands have a worse prognosis than younger patients: A population-based study

Robin W.M. Vernooij, Inge M. van Oort, T. De Reijke, K. Aben

Shared genetics underlying epidemiological association between endometriosis and ovarian cancer

Yi Lu, Gabriel Cuéllar-Partida, Jodie N. Painter, Dale R. Nyholt et autres